Basel Medical Group Shares Slump 18% on 1-for-12 Reverse Split Plan
BMGL•Shares of Basel Medical Group fell 18% after board approved a 1-for-12 reverse split effective June 22, 2026, to meet Nasdaq’s $1 minimum bid rule. The consolidation will cut outstanding shares from 18.8 million to 1.57 million, following a net loss of $8.4 million vs $1.5 million a year earlier.
1. Board Approves 1-for-12 Reverse Stock Split
The board approved a 1-for-12 reverse stock split effective June 22, 2026, consolidating every 12 existing shares into one to reduce the outstanding share count. This move aims to boost the per-share price to comply with Nasdaq’s $1 minimum bid requirement.
2. Nasdaq Minimum Bid Price Compliance
Basel Medical Group received a violation notice in January after its shares remained below $1 for 30 consecutive business days. The company has until July 21, 2026, to regain compliance or face possible delisting.
3. Financial Performance Trends
For the fiscal year ended June 2025, the company reported a net loss of $8.4 million compared with a $1.5 million loss a year earlier. The widening deficit reflects increased operating expenses and ongoing investment in clinical development programs.
4. Market Reaction and Outlook
Shares slumped more than 18% on the reverse split announcement, reversing a three-day rally, while short interest stands at 0.1%, its lowest level in a year. Investor sentiment remains mixed as the consolidation may reduce liquidity even as it addresses compliance risk.
